TMQ vs. GNOM

Last updated Apr 2, 2026

Compare and contrast key facts about Trilogy Metals Inc. (TMQ) and Global X Genomics & Biotechnology ETF (GNOM).

GNOM is a passively managed fund by Global X that tracks the performance of the Solactive Genomics Index. It was launched on Apr 5, 2019.

Performance

TMQ vs. GNOM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Trilogy Metals Inc. (TMQ) and Global X Genomics & Biotechnology ETF (GNOM). The values are adjusted to include any dividend payments, if applicable.

TMQ vs. GNOM - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
TMQ Trilogy Metals Inc.	-12.53%	271.55%	169.77%	-21.82%	-66.67%	-17.50%	-23.08%	3.17%
GNOM Global X Genomics & Biotechnology ETF	-2.79%	18.65%	-15.99%	-8.63%	-36.27%	-15.93%	51.52%	1.56%

Returns By Period

In the year-to-date period, TMQ achieves a -12.53% return, which is significantly lower than GNOM's -2.79% return.

TMQ

• 1D: 5.01%
• 1M: -16.78%
• YTD: -12.53%
• 6M: 65.35%
• 1Y: 137.11%
• 3Y*: 91.96%
• 5Y*: 11.58%
• 10Y*: 26.13%

GNOM

• 1D: 1.02%
• 1M: -6.22%
• YTD: -2.79%
• 6M: 12.23%
• 1Y: 44.15%
• 3Y*: -3.13%
• 5Y*: -13.13%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

TMQ vs. GNOM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TMQ

TMQ Risk / Return Rank: 79
TMQ Sharpe Ratio Rank: 61
TMQ Sortino Ratio Rank: 96
TMQ Omega Ratio Rank: 93
TMQ Calmar Ratio Rank: 77
TMQ Martin Ratio Rank: 69

GNOM

GNOM Risk / Return Rank: 73
GNOM Sharpe Ratio Rank: 75
GNOM Sortino Ratio Rank: 77
GNOM Omega Ratio Rank: 68
GNOM Calmar Ratio Rank: 78
GNOM Martin Ratio Rank: 69

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TMQ vs. GNOM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Trilogy Metals Inc. (TMQ) and Global X Genomics & Biotechnology ETF (GNOM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	TMQ	GNOM	Difference
Sharpe ratio Return per unit of total volatility	0.58	1.43	-0.84
Sortino ratio Return per unit of downside risk	3.72	2.04	+1.68
Omega ratio Gain probability vs. loss probability	1.45	1.26	+0.20
Calmar ratio Return relative to maximum drawdown	2.06	2.25	-0.19
Martin ratio Return relative to average drawdown	3.53	7.43	-3.90
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

TMQ vs. GNOM - Sharpe Ratio Comparison

The current TMQ Sharpe Ratio is 0.58, which is lower than the GNOM Sharpe Ratio of 1.43. The chart below compares the historical Sharpe Ratios of TMQ and GNOM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	TMQ	GNOM	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.58	1.43	-0.84
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.09	-0.39	+0.48
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.26	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.02	-0.13	+0.11

Correlation

The correlation between TMQ and GNOM is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

TMQ vs. GNOM - Dividend Comparison

TMQ has not paid dividends to shareholders, while GNOM's dividend yield for the trailing twelve months is around 1.41%.

	TTM	2025	2024	2023	2022	2021	2020
TMQ Trilogy Metals Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
GNOM Global X Genomics & Biotechnology ETF	1.41%	1.37%	0.00%	0.00%	0.00%	0.03%	0.14%

Drawdowns

TMQ vs. GNOM - Drawdown Comparison

The maximum TMQ drawdown since its inception was -96.55%, which is greater than GNOM's maximum drawdown of -75.00%. Use the drawdown chart below to compare losses from any high point for TMQ and GNOM.

Drawdown Indicators

	TMQ	GNOM	Difference
Max Drawdown Largest peak-to-trough decline	-96.55%	-75.00%	-21.55%
Max Drawdown (1Y) Largest decline over 1 year	-69.62%	-18.17%	-51.45%
Max Drawdown (5Y) Largest decline over 5 years	-87.61%	-72.29%	-15.32%
Max Drawdown (10Y) Largest decline over 10 years	-88.01%	—	—
Current Drawdown Current decline from peak	-64.43%	-59.83%	-4.60%
Average Drawdown Average peak-to-trough decline	-72.11%	-40.12%	-31.99%
Ulcer Index Depth and duration of drawdowns from previous peaks	40.57%	5.51%	+35.06%

Volatility

TMQ vs. GNOM - Volatility Comparison

Trilogy Metals Inc. (TMQ) has a higher volatility of 19.20% compared to Global X Genomics & Biotechnology ETF (GNOM) at 10.76%. This indicates that TMQ's price experiences larger fluctuations and is considered to be riskier than GNOM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TMQ	GNOM	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.20%	10.76%	+8.44%
Volatility (6M) Calculated over the trailing 6-month period	142.85%	19.71%	+123.14%
Volatility (1Y) Calculated over the trailing 1-year period	237.38%	31.21%	+206.17%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	128.10%	33.65%	+94.45%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	102.28%	34.30%	+67.98%